Artiva Stock on Watch with EULAR Data and Jefferies in Play
Artiva Biotherapeutics shares traded up on Wednesday, moving against the Nasdaq’s drop, with traders focused on the company’s spot at the Jefferies healthcare event and new attention for its AlloNK autoimmune program. Shares last changed hands at $6.97, up 10 cents, or 1.5%. The Nasdaq Composite was down 0.9%. Artiva is set to join a fireside chat at the Jefferies Global Healthcare Conference in New York at 9:20 a.m. EDT on Thursday. That appearance lands as the European Alliance of Associations for Rheumatology meeting is happening in London from June 3 to June 6.